Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
62
HRMY Quote, Financials, Valuation and Earnings
Last price:
$36.95
Seasonality move
:
-9.03%
Day range:
$37.02 - $37.68
52-week range:
$25.52 - $40.93
Dividend yield:
0%
P/E ratio:
11.78x
P/S ratio:
2.65x
P/B ratio:
2.58x
Volume:
400.3K
Avg. volume:
720.5K
1-year change:
8.75%
Market cap:
$2.2B
Revenue:
$714.7M
EPS (TTM):
$3.18
Analysts' Opinion
-
Consensus RatingHarmony Biosciences Holdings, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $46.18, Harmony Biosciences Holdings, Inc. has an estimated upside of 23.42% from its current price of $37.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $32.00 representing 100% downside risk from its current price of $37.42.
Fair Value
-
According to the consensus of 8 analysts, Harmony Biosciences Holdings, Inc. has 23.42% upside to fair value with a price target of $46.18 per share.
HRMY vs. S&P 500
-
Over the past 5 trading days, Harmony Biosciences Holdings, Inc. has underperformed the S&P 500 by -1.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Harmony Biosciences Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Harmony Biosciences Holdings, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Harmony Biosciences Holdings, Inc. reported revenues of $239.5M.
Earnings Growth
-
Harmony Biosciences Holdings, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Harmony Biosciences Holdings, Inc. reported earnings per share of $0.87.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
2.65x
EV / EBIT:
7.58x
EV / Revenue:
2.07x
PEG ratio (5yr expected):
0.23x
EV / Free cash flow:
5.76x
Price / Operating cash flow:
7.37x
Enterprise value / EBITDA:
6.85x
Gross Profit (TTM):
$617.9M
Return On Assets:
17.52%
Net Income Margin (TTM):
22.48%
Return On Equity:
25.9%
Return On Invested Capital:
19.81%
Operating Margin:
27.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $541.9M | $681.9M | $825.9M | $186M | $239.5M | |
| Gross Profit | $413.1M | $512.5M | $617.9M | $137.3M | $173.8M | |
| Operating Income | $199.4M | $175.3M | $225.6M | $61.7M | $65.5M | |
| EBITDA | $223.7M | $199.6M | $249.5M | $67.7M | $71.5M | |
| Diluted EPS | $2.47 | $2.11 | $3.18 | $0.79 | $0.87 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $240.7M | $382.1M | $463M | $522.4M | $838.8M | |
| Total Assets | $391.1M | $643.5M | $777.8M | $928.1M | $1.2B | |
| Current Liabilities | $47.6M | $107.4M | $112.4M | $161.3M | $223.4M | |
| Total Liabilities | $239.1M | $299.6M | $296.4M | $331.3M | $373.1M | |
| Total Equity | $152M | $343.9M | $481.3M | $596.8M | $835.1M | |
| Total Debt | $192.1M | $193.1M | $198M | $183.7M | $168.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $169.4M | $220.9M | $297.6M | $70.5M | $108.7M | |
| Cash From Investing | -$57.3M | -$96.4M | -$29.2M | $745K | -$4.8M | |
| Cash From Financing | -$49.4M | -$61.8M | -$8.8M | -$1.2M | -$3M | |
| Free Cash Flow | $169.2M | $220.2M | $296.9M | $70.5M | $108.7M | |
HRMY
Sector
Market Cap
$2.2B
$28.1M
Price % of 52-Week High
91.42%
50%
Dividend Yield
0%
0%
Shareholder Yield
-0.78%
-1.54%
1-Year Price Total Return
8.75%
-17.67%
Beta (5-Year)
0.839
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$38.09
200-day SMA
Buy
Level
$33.22
Bollinger Bands (100)
Buy
Level
28.98 - 37.72
Chaikin Money Flow
Sell
Level
-636.9K
20-day SMA
Sell
Level
$38.54
Relative Strength Index (RSI14)
Buy
Level
51.98
ADX Line
Buy
Level
37.57
Williams %R
Buy
Level
-89.6104
50-day SMA
Buy
Level
$34.64
MACD (12, 26)
Buy
Level
0.80
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-18.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.3036)
Buy
CA Score
(Annual)
Level (1.3549)
Buy
Beneish M-Score
(Annual)
Level (-2.6745)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.4579)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Stock Forecast FAQ
In the current month, HRMY has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The HRMY average analyst price target in the past 3 months is $46.18.
-
Where Will Harmony Biosciences Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Harmony Biosciences Holdings, Inc. share price will rise to $46.18 per share over the next 12 months.
-
What Do Analysts Say About Harmony Biosciences Holdings, Inc.?
Analysts are divided on their view about Harmony Biosciences Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Harmony Biosciences Holdings, Inc. is a Sell and believe this share price will drop from its current level to $32.00.
-
What Is Harmony Biosciences Holdings, Inc.'s Price Target?
The price target for Harmony Biosciences Holdings, Inc. over the next 1-year time period is forecast to be $46.18 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is HRMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Harmony Biosciences Holdings, Inc. is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HRMY?
You can purchase shares of Harmony Biosciences Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Harmony Biosciences Holdings, Inc. shares.
-
What Is The Harmony Biosciences Holdings, Inc. Share Price Today?
Harmony Biosciences Holdings, Inc. was last trading at $36.95 per share. This represents the most recent stock quote for Harmony Biosciences Holdings, Inc.. Yesterday, Harmony Biosciences Holdings, Inc. closed at $37.42 per share.
-
How To Buy Harmony Biosciences Holdings, Inc. Stock Online?
In order to purchase Harmony Biosciences Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HRMY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HRMY
Sector
P/E ratio
11.78x
23.88x
PEG ratio
0.23x
-0.01x
P/B ratio
2.58x
1.82x
Price / LTM sales
2.65x
1.59x
Growth Metrics
HRMY
Sector
Revenue growth
28.71%
4.73%
Earnings growth
9.2%
11.11%
Revenue (5-year growth)
160.18%
6.46%
Earnings forecast
$1.09
-$0.18
Profitability
HRMY
Sector
Profitability FY 2024
$534.1M
$3.6M
Return on invested capital
19.81%
-31.77%
Return on assets
17.52%
-28.18%
Return on equity
25.9%
-37.47%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
HRMY
Sector
Total cash
$672.6M
$26.3M
Short term investments
$14.2M
$26M
Total assets
$999.2M
$76.9M
Long term debt
$168.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 5.11% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.83% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 9.63% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
